Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant.

We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor. Despite improvement in bone mineralization and subsequent parathyroidectomy with normalization of the serum calcium level, the combination of chronic lung disease, osteomalacia, and poor thoracic cage growth ultimately proved fatal. Pamidronate therapy seems to be safe in the short-term and effective in helping control hypercalcemia even in the very premature infant, allowing for planned surgical intervention when it becomes feasible.
AuthorsLisa Fox, Joel Sadowsky, Kevin P Pringle, Alexa Kidd, Jean Murdoch, David E C Cole, Esko Wiltshire
JournalPediatrics (Pediatrics) Vol. 120 Issue 5 Pg. e1350-4 (Nov 2007) ISSN: 1098-4275 [Electronic] United States
PMID17974727 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Diphosphonates
  • pamidronate
  • Diphosphonates (therapeutic use)
  • Fatal Outcome
  • Female
  • Humans
  • Hyperparathyroidism (drug therapy, radiography)
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Infant, Very Low Birth Weight

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: